| Schedule of Segment Financial Information |
Schedule
of Segment Financial Information
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
Three
Months Ended June 30, | | |
Six
Months Ended June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Research and development | |
$ | | | |
$ | | | |
$ | | | |
$ | | |
| Clinical | |
| 78,263 | | |
| (20,676 | ) | |
| 78,263 | | |
| 705,645 | |
| Chemistry, manufacturing and controls and nonclinical | |
| 27,756 | | |
| 166,478 | | |
| 60,258 | | |
| 311,179 | |
| Personnel related | |
| 106,544 | | |
| 472,033 | | |
| 457,766 | | |
| 882,152 | |
| Total research and development | |
$ | 212,563 | | |
$ | 617,835 | | |
$ | 596,287 | | |
$ | 1,898,976 | |
| Selling, general and administrative | |
| | | |
| | | |
| | | |
| | |
| Compliance | |
| 1,289,233 | | |
| 755,020 | | |
| 2,301,029 | | |
| 1,474,664 | |
| Marketing | |
| 626,905 | | |
| - | | |
| 833,238 | | |
| - | |
| Commercial readiness | |
| 128,947 | | |
| - | | |
| 128,947 | | |
| - | |
| Personnel related | |
| 755,919 | | |
| 399,876 | | |
| 1,080,448 | | |
| 738,895 | |
| Total selling, general and administrative | |
$ | 2,801,004 | | |
$ | 1,154,896 | | |
$ | 4,343,662 | | |
$ | 2,213,559 | |
| Interest income | |
| 46,504 | | |
| 71,638 | | |
| 125,180 | | |
| 107,855 | |
| Net loss | |
$ | (2,967,063 | ) | |
$ | (1,701,093 | ) | |
$ | (4,814,769 | ) | |
$ | (4,004,680 | ) |
|